可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1]Dzau VJ, Gibbons GH. Vascular remodeling: Mechanisms and implications[J]. Cardiovasc Pharmacol, 1993, 21(suppl1):S1-S5.
[2]王关嵩,钱桂生. 低氧肺血管重构的分子机制研究概况及展望[J]. 第三军医大学学报, 2009, 31(1):3-5.
[3]McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension[J]. Eur Respir J, 2005, 25(2):244-249.
[4]Dempsie Y, MacLean MR. Pulmonary hypertension:therapeutic targets within the serotonin system[J]. Br J Pharmacol, 2008, 155(4):455-462.
[5]张洪玉,邝士光. 肺动脉高压发病机制及治疗进展[J]. 中国医刊, 2004, 39(5):5-7.
[6]Takeoka M, Ehara T, Sagara J, et al. Calponin h1 induced a flattene morphology and suppressed the growth of fibrosarcoma HT1080 cells[J]. Eur J Cancer, 2002, 38(3):436-442.
[7]刘海莲,张玉顺,王佳兴,等. 波生坦对慢性低氧性肺动脉高压大鼠右心室肥厚及缝隙连接蛋白(Cx)43表达的影响[J]. 心脏杂志, 2010,22(1):51-55.
[8]Barth PJ, Kimpel C, Roy S, et al. An improved mathematical approach for the assessment of the medial thickness of pulmonary arteries[J]. Pathol Res Pract, 1993, 189(4):567-576.
[9]Li H, Jiang T, Yang J, et al. Relationship between calponin h1 and TGFβ1inratmesangialcells[J]. ChinNephrol,2005,21(4):213-218.
[10]Stephen HL, Richard NC. Endothelin antagonism in pulmonary arterial hypertension[J]. Semin Respir Crit Care Med, 2005, 26(4):402-408.
[11]GalieN, ManesA, BranziA. The endothelin system in pulmonary arterial hypertension[J]. Cardiovasc Res, 2004, 61(2):227-237.
[12]王佳兴,张玉顺,刘海莲,等. 波生坦对高原性肺水肿的治疗作用[J]. 现代生物医学进展, 2009, 9(4):693-695.